NM-2201 |
|
| Legal status |
|
|---|
|
Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| CompTox Dashboard (EPA) | |
|---|
|
| Formula | C24H22FNO2 |
|---|
| Molar mass | 375.443 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
FCCCCCN1C=C(C(OC2=C(C=CC=C3)C3=CC=C2)=O)C4=CC=CC=C41
|
InChI=1S/C24H22FNO2/c25-15-6-1-7-16-26-17-21(20-12-4-5-13-22(20)26)24(27)28-23-14-8-10-18-9-2-3-11-19(18)23/h2-5,8-14,17H,1,6-7,15-16H2 Key:PRGFSQYZCKCBQO-UHFFFAOYSA-N
|
NM-2201 (also known as CBL-2201 and NA-5F-PIC[1]) is an indole-based synthetic cannabinoid that presumably has similar properties to the closely related 5F-PB-22 and NNE1, which are both full agonists and unselectively bind to CB1 and CB2 receptors with low nanomolar affinity.[2][3][4][5]
Pharmacology
NM-2201 acts as a full agonist with a binding affinity of 0.332 nM at CB1 and 0.732 nM at CB2 cannabinoid receptors.[6] It has been linked to serious adverse events in users.[7]
Legal status
NM-2201 is specifically banned in Sweden,[8] Germany (Anlage II),[9] and Japan[10] but is also controlled in many other jurisdictions under analogue laws.
On May 30, 2018 the United States Drug Enforcement Administration, Department of Justice published a notice of intent to place NM-2201 and 4 other synthetic cannabinoids in schedule I of the Controlled Substances Act. This notice went into effect on June 29, 2018.[11]
Use
NM-2201 was linked to an incident in December 2015 where 25-30 people in Ocala, FL were taken to hospitals after experiencing seizures.[11]
See also
References
- ^ Pulver B, Fischmann S, Gallegos A, Christie R (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis. 15 (3): 255–276. doi:10.1002/dta.3403. PMID 36346325.
- ^ Kondrasenko AA, Goncharov EV, Dugaev KP, Rubaylo AI (December 2015). "CBL-2201. Report on a new designer drug: Napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate". Forensic Science International. 257: 209–213. doi:10.1016/j.forsciint.2015.08.023. PMID 26386336.
- ^ "NM-2201". Cayman Chemical. Retrieved 9 July 2015.
- ^ Namera A, Kawamura M, Nakamoto A, Saito T, Nagao M (2015). "Comprehensive review of the detection methods for synthetic cannabinoids and cathinones". Forensic Toxicology. 33 (2): 175–194. doi:10.1007/s11419-015-0270-0. PMC 4525208. PMID 26257831.
- ^ Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Baranovsky A, Shafran Y (November 2014). "Synthetic cannabinoids as designer drugs: new representatives of indol-3-carboxylates series and indazole-3-carboxylates as novel group of cannabinoids. Identification and analytical data". Forensic Science International. 244: 263–75. doi:10.1016/j.forsciint.2014.09.013. PMID 25305529.
- ^ Hess C, Schoeder CT, Pillaiyar T, Madea B, Müller CE (2016). "Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice". Forensic Toxicology. 34 (2): 329–343. doi:10.1007/s11419-016-0320-2. PMC 4929166. PMID 27429655.
- ^ Samra K, Boon IS, Packer G, Jacob S (April 2017). "black mamba". BMJ Case Reports. 2017: bcr–2016–218431. doi:10.1136/bcr-2016-218431. PMC 5534782. PMID 28433979.
- ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara" [Cannabinoids are proposed to be classified as a health hazard] (in Swedish). Folkhälsomyndigheten (The Public Health Authority). Retrieved 9 July 2015.
- ^ "Gesetz über den Verkehr mit Betäubungsmitteln Anlage II" [Law on the Traffic in Narcotics Annex II]. www.gesetze-im-internet.de (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved 24 October 2016.
- ^ Diao X, Carlier J, Zhu M, Pang S, Kronstrand R, Scheidweiler KB, et al. (January 2017). "In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201)". Forensic Toxicology. 35 (1): 20–32. doi:10.1007/s11419-016-0326-9. PMC 5342258. PMID 28286577.
- ^ a b "2018 - Temporary Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA Into Schedule I". www.deadiversion.usdoj.gov. Retrieved 2018-06-15.
|
|---|
Phytocannabinoids (comparison) | | Cannabibutols | |
|---|
| Cannabichromenes | |
|---|
| Cannabicyclols | |
|---|
| Cannabidiols | |
|---|
| Cannabielsoins | |
|---|
| Cannabigerols | |
|---|
| Cannabiphorols | |
|---|
| Cannabinols |
- CBN
- CBNA
- CBN-C1
- CBN-C2
- CBN-C4
- CBNM
- CBND
- CBNP
- CBVD
|
|---|
| Cannabitriols | |
|---|
| Cannabivarins | |
|---|
| Delta-3-tetrahydrocannabinols | |
|---|
| Delta-4-tetrahydrocannabinols | |
|---|
| Delta-7-tetrahydrocannabinols | |
|---|
| Delta-8-tetrahydrocannabinols |
- Delta-8-THC
- Delta-8-THCB
- Delta-8-THCP
- Delta-8-THCV
|
|---|
| Delta-9-tetrahydrocannabinols | |
|---|
| Delta-10-Tetrahydrocannabinols | |
|---|
| Delta-11-Tetrahydrocannabinols | |
|---|
| Miscellaneous cannabinoids | |
|---|
| Active metabolites | |
|---|
|
|---|
| Endocannabinoids | |
|---|
Synthetic cannabinoid receptor agonists / neocannabinoids | Classical cannabinoids (dibenzopyrans) | |
|---|
Non-classical cannabinoids |
- Cannabicyclohexanol
- Cannabinor
- CBD-DMH
- CP 47,497
- (C6)-CP 47,497
- (C9)-CP 47,497
- CP 55,244
- CP 55,940
- Delta-6-Cannabidiol
- Etrinabdione
- HU-320
- HU-331
- HU-336
- HU-345
- HU-446
- HU-465
- HU-910
- HUF-101
- Nonabine
- O-1376
- O-1422
- O-1601
- O-1656
- O-1657
- O-1660
- O-1663
- O-1871
- Onternabez (HU-308)
- SPA-229
- Tinabinol
|
|---|
| Adamantoylindoles | |
|---|
| Benzimidazoles |
- AZ-11713908
- AZD-1940
- BIM-018
- FUBIMINA
- MCHB-1
- PF-03550096
- RQ-00202730
|
|---|
| Benzoylindoles |
- 1-Butyl-3-(2-methoxybenzoyl)indole
- 1-Butyl-3-(4-methoxybenzoyl)indole
- 1-Pentyl-3-(2-methoxybenzoyl)indole
- AM-630
- AM-679
- AM-694
- AM-1241
- AM-2233
- GW-405,833 (L-768,242)
- Pravadoline
- RCS-4
- WIN 54,461
|
|---|
| Cyclohexylphenols | |
|---|
| Eicosanoids |
- AM-883
- AM-1346
- ACEA
- ACPA
- Methanandamide (AM-356)
- O-585
- O-689
- O-1812
- O-1860
- O-1861
|
|---|
Indazole-3- carboxamides | |
|---|
| Indole-3-carboxamides |
- 4'F-CUMYL-5F-PICA
- 5F-ADBICA
- 5F-EDMB-PICA
- 5F-MDMB-PICA
- 5F-NNE1
- 5F-PCN
- 5F-SDB-006
- AB-FUBICA
- AB-PICA
- ADBICA
- ADB-FUBICA
- APICA
- BMS-F
- CUMYL-BICA
- CUMYL-CBMICA
- CUMYL-CHMICA
- CUMYL-NBMICA
- CUMYL-PICA
- CUMYL-5F-PICA
- FDU-NNE1
- MDMB-CHMICA
- MMB-CHMICA
- MMB-2201
- MN-25 (UR-12)
- NNE1
- PX-1
- Org 28312
- Org 28611
- SDB-006
- STS-135
|
|---|
| Indole-3-carboxylates | |
|---|
| Naphthoylindazoles | |
|---|
| Naphthoylindoles |
- 5F-JWH-398
- AM-1220
- AM-1221
- AM-1235
- AM-2201
- AM-2232
- CHM-081
- EAM-2201
- FUB-JWH-018
- JWH-004
- JWH-007
- JWH-009
- JWH-011
- JWH-015
- JWH-016
- JWH-018
- JWH-019
- JWH-020
- JWH-042
- JWH-043
- JWH-046
- JWH-047
- JWH-048
- JWH-049
- JWH-050
- JWH-070
- JWH-072
- JWH-073
- JWH-076
- JWH-077
- JWH-079
- JWH-080
- JWH-081
- JWH-082
- JWH-083
- JWH-093
- JWH-094
- JWH-095
- JWH-096
- JWH-097
- JWH-098
- JWH-099
- JWH-100
- JWH-116
- JWH-120
- JWH-122
- JWH-148
- JWH-149
- JWH-151
- JWH-153
- JWH-159
- JWH-160
- JWH-163
- JWH-164
- JWH-165
- JWH-166
- JWH-180
- JWH-181
- JWH-182
- JWH-189
- JWH-193
- JWH-198
- JWH-200
- JWH-210
- JWH-211
- JWH-212
- JWH-213
- JWH-234
- JWH-235
- JWH-236
- JWH-239
- JWH-240
- JWH-241
- JWH-242
- JWH-258
- JWH-259
- JWH-260
- JWH-261
- JWH-262
- JWH-265
- JWH-266
- JWH-267
- JWH-268
- JWH-387
- JWH-398
- JWH-416
- JWH-417
- JWH-422
- JWH-423
- JWH-424
- JWH-425
- MAM-1220
- MAM-2201
- NE-CHMIMO
|
|---|
| Naphthoylpyrroles |
- JWH-030
- JWH-031
- JWH-032
- JWH-033
- JWH-036
- JWH-044
- JWH-045
- JWH-145
- JWH-146
- JWH-147
- JWH-150
- JWH-156
- JWH-243
- JWH-244
- JWH-245
- JWH-246
- JWH-292
- JWH-293
- JWH-307
- JWH-308
- JWH-309
- JWH-346
- JWH-347
- JWH-348
- JWH-363
- JWH-364
- JWH-365
- JWH-366
- JWH-367
- JWH-368
- JWH-369
- JWH-370
- JWH-371
- JWH-372
- JWH-373
|
|---|
| Naphthylmethylindenes | |
|---|
| Naphthylmethylindoles |
- JWH-175
- JWH-184
- JWH-185
- JWH-192
- JWH-194
- JWH-195
- JWH-196
- JWH-197
- JWH-199
|
|---|
| Phenylacetylindoles |
- Cannabipiperidiethanone
- JWH-167
- JWH-201
- JWH-202
- JWH-203
- JWH-204
- JWH-205
- JWH-206
- JWH-207
- JWH-208
- JWH-209
- JWH-237
- JWH-248
- JWH-249
- JWH-250
- JWH-251
- JWH-252
- JWH-253
- JWH-302
- JWH-303
- JWH-304
- JWH-305
- JWH-306
- JWH-311
- JWH-312
- JWH-313
- JWH-314
- JWH-315
- JWH-316
- RCS-8
|
|---|
| Pyrazolecarboxamides |
- 5F-AB-FUPPYCA
- 5F-AMPPPCA
- AB-CHFUPYCA
|
|---|
Tetramethylcyclo- propanoylindazoles | |
|---|
Tetramethylcyclo- propanoylindoles | |
|---|
| Others |
- 2F-QMPSB
- 4-HTMPIPO
- 4CN-CUMYL-BUT7AICA
- 5F-3-pyridinoylindole
- 5F-ADB-P7AICA
- 5F-CUMYL-P7AICA
- 5F-CUMYL-PEGACLONE
- 5F-PY-PICA
- 5F-PY-PINACA
- A-836,339
- A-955,840
- A-PBITMO
- A-PONASA
- AB-001
- ADB-FUBHQUCA
- ADB-FUBIATA
- ADB-P7AICA
- AM-1248
- AM-1714
- Abnormal cannabidiol
- BAY 38-7271
- BAY 59-3074
- BzODZ-EPyr
- CB-13
- CB-86
- CBS-0550
- CUMYL-4CN-B7AICA
- CUMYL-CB-MEGACLONE
- CUMYL-CH-MEGACLONE
- CUMYL-PEGACLONE
- Cis-THC
- EG-018
- GSK-554,418A
- GW-842,166X
- HHCP-O-acetate
- HHCH
- Iso-THC
- JTE 7-31
- LASSBio-881
- LBP-1
- Leelamine
- MDA-19
- MDA-7
- MEPIRAPIM
- NESS-040C5
- NMDMSB
- NMP-7
- O-1269
- O-1270
- O-1399
- O-1602
- O-2220
- O-889
- Olorinab
- PF-03550096
- PSB-SB-1202
- PTI-1
- PTI-2
- PTI-3
- QMPSB
- S-444,823
- S-777,469
- SER-601
- THCP-O-acetate
- Tedalinab
- URB-447
- VSN-16
- Vicasinabin
- WIN 55,212-2
- WIN 56,098
|
|---|
|
|---|
| Allosteric CBRTooltip Cannabinoid receptor ligands |
- AEF0117
- GAT100
- Org 27569
- Org 27759
- Org 29647
- PSNCBAM-1
- Pregnenolone
- RTI-371
- ZCZ-011
|
|---|
Endocannabinoid enhancers (inactivation inhibitors) | |
|---|
Anticannabinoids (antagonists/inverse agonists/antibodies) |
- ABD459
- AM-251
- AM-281
- AM-630
- AM-1387
- AM-4113
- AM-6527
- AM-6545
- Amauromine
- ANEB-001
- AZD-2207
- BML-190
- CAY-10508
- CB-25
- CB-52
- CB-86
- CE-178253
- COR170
- Drinabant (AVE1625)
- Hemopressin
- Ibipinabant (SLV319)
- JD-5037
- JTE-907
- LH-21
- LY-320,135
- MDA-77
- MJ-15
- MK-9470
- Monlunabant
- MRL-650
- NESS-0327
- NIDA-41020
- O-606
- O-1184
- O-1248
- O-1918
- O-2050
- O-2654
- Otenabant (CP-945,598)
- PF-514273
- PGN36
- PipISB
- PSB-SB-487
- Rezosicone
- Rimonabant (SR141716)
- Rosonabant (E-6776)
- SLV 319
- SR-144,528
- Surinabant (SR147778)
- Taranabant (MK-0364)
- TC-C 14G
- TM-38837
- VCHSR
- Voacamine
- Zevaquenabant
|
|---|
- See also: Cannabinoid receptor modulators (cannabinoids by pharmacology)
- List of: AM cannabinoids
- JWH cannabinoids
- Designer drugs § Synthetic cannabimimetics
|
|
|---|
Receptor (ligands) | | CB1Tooltip Cannabinoid receptor type 1 | Agonists (abridged, full list) | |
|---|
| Inverse agonists | |
|---|
| Antagonists | |
|---|
|
|---|
| CB2Tooltip Cannabinoid receptor type 2 | | Agonists |
- 2-AG
- 2-AGE (noladin ether)
- 3,3'-Diindolylmethane
- 4-O-Methylhonokiol
- α-Amyrin · β-Amyrin
- A-796,260
- A-834,735
- A-836,339
- AM-1172
- AM-1221
- AM-1235
- AM-1241
- AM-2232
- Anandamide
- AZ-11713908
- Cannabinol
- Caryophyllene
- CB-13
- CBS-0550
- CP 55,940
- GW-405,833 (L-768,242)
- GW-842,166X
- HU-308
- JTE 7-31
- JWH-007
- JWH-015
- JWH-018
- JWH-73
- JWH-133
- L-759,633
- L-759,656
- Lenabasum (anabasum)
- Magnolol
- MDA-19
- Nabitan
- NADA
- Olorinab (APD-371)
- PF-03550096
- S-444,823
- SER-601
- Serinolamide A
- UR-144
- Tedalinab
- THC (dronabinol)
- THCV
- Tetrahydromagnolol
- Virodhamine
|
|---|
| Antagonists | |
|---|
|
|---|
NAGly (GPR18) | |
|---|
| GPR55 | | Agonists | |
|---|
| Antagonists |
- Cannabidiol
- CID-16020046
- ML-191
- ML-192
- ML-193
- O-1918
- PSB-SB-487
- PSB-SB-1202
- PSB-SB-1203
- Tetrahydromagnolol
|
|---|
|
|---|
| GPR119 | |
|---|
|
|---|
Transporter (modulators) | | eCBTsTooltip Endocannabinoid transporter | |
|---|
|
|---|
Enzyme (modulators) | | FAAHTooltip Fatty acid amide hydrolase | |
|---|
| MAGL |
- Inhibitors: ABX-1431
- IDFP
- JJKK 048
- JW 642
- JZL-184
- JZL-195
- JZP-361
- KML 29
- MAFP
- MJN110
- NAM
- Pristimerin
- URB-602
|
|---|
| ABHD6 |
- Inhibitors: JZP-169
- JZP-430
- KT182
- KT185
- KT195
- KT203
- LEI-106
- ML294
- ML295
- ML296
- UCM710
- WWL-70
|
|---|
| ABHD12 | |
|---|
|
|---|
| Others |
- Others: 2-PG (directly potentiates activity of 2-AG at CB1 receptor)
- ARN-272 (FAAH-like anandamide transporter inhibitor)
|
|---|
- See also
- Receptor/signaling modulators
- Cannabinoids (cannabinoids by structure)
|